Innoviva, Inc. (INVA)
NASDAQ: INVA · Real-Time Price · USD
23.22
+0.32 (1.42%)
May 11, 2026, 10:06 AM EDT - Market open
Innoviva Revenue
Innoviva had revenue of $97.99M in the quarter ending March 31, 2026, with 10.56% growth. This brings the company's revenue in the last twelve months to $420.69M, up 13.75% year-over-year. In the year 2025, Innoviva had annual revenue of $411.33M with 14.67% growth.
Revenue (ttm)
$420.69M
Revenue Growth
+13.75%
P/S Ratio
3.96
Revenue / Employee
$2,645,849
Employees
159
Market Cap
1.71B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 411.33M | 52.62M | 14.67% |
| Dec 31, 2024 | 358.71M | 48.25M | 15.54% |
| Dec 31, 2023 | 310.46M | -20.88M | -6.30% |
| Dec 31, 2022 | 331.34M | -60.53M | -15.45% |
| Dec 31, 2021 | 391.87M | 55.07M | 16.35% |
| Dec 31, 2020 | 336.79M | 75.78M | 29.03% |
| Dec 31, 2019 | 261.02M | 12.00K | - |
| Dec 31, 2018 | 261.00M | 43.79M | 20.16% |
| Dec 31, 2017 | 217.22M | 83.65M | 62.63% |
| Dec 31, 2016 | 133.57M | 79.62M | 147.58% |
| Dec 31, 2015 | 53.95M | 45.52M | 539.74% |
| Dec 31, 2014 | 8.43M | 3.90M | 86.08% |
| Dec 31, 2013 | 4.53M | -1.08M | -19.26% |
| Dec 31, 2012 | 5.61M | -18.90M | -77.10% |
| Dec 31, 2011 | 24.51M | 289.00K | 1.19% |
| Dec 31, 2010 | 24.22M | -151.00K | -0.62% |
| Dec 31, 2009 | 24.37M | 1.28M | 5.53% |
| Dec 31, 2008 | 23.10M | 1.09M | 4.97% |
| Dec 31, 2007 | 22.00M | 2.42M | 12.33% |
| Dec 31, 2006 | 19.59M | 7.53M | 62.49% |
| Dec 31, 2005 | 12.05M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novavax | 596.34M |
| Ardelyx | 427.68M |
| Vericel | 292.09M |
| Nuvation Bio | 143.05M |
| Nurix Therapeutics | 71.78M |
| Viridian Therapeutics | 70.92M |
| Recursion Pharmaceuticals | 66.41M |
| Agios Pharmaceuticals | 66.05M |
INVA News
- 4 days ago - Innoviva price target raised to $42 from $35 at BTIG - TheFly
- 4 days ago - Innoviva reports Q1 EPS $2.22 vs (74c) last year - TheFly
- 4 days ago - Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress - Business Wire
- 2 months ago - Innoviva Specialty Therapeutics Earns Strong Performance Rating in Access to Medicine Foundation's 2026 Antimicrobial Resistance Benchmark Report - Business Wire
- 2 months ago - 3 Small-Cap ‘Strong Buy’ Stocks with Big Upside in 2026, According to Analysts - TipRanks
- 2 months ago - Innoviva Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference - Transcripts
- 2 months ago - Innoviva price target raised to $32 from $31 at Cantor Fitzgerald - TheFly
- 2 months ago - Innoviva reports Q4 EPS $1.94 vs. 26c last year - TheFly